• Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

When patients with Crohn’s disease in sustained remission stopped taking infliximab for a median 7 years, almost one fifth did not require retreatment or have a major complication, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Fewer than one fifth of patients required surgery or developed a complex perianal fistula. Increasing numbers of patients

Read more
  • Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Rates of adequate serologic response to Haemophilus influenzae B (HiB) and tetanus vaccines are similar among infants born to women with inflammatory bowel diseases (IBD) treated with immunomodulator or biologic agents compared to women who did not receive these immunosuppressive drugs during pregnancy, researchers report in the January issue of Clinical Gastroenterology

Read more

What Happens to Infants Whose Mothers Took Anti-TNF Agents During Pregnancy?

Anti-tumor necrosis factor (TNF) agents can be detected in infants born to mothers with inflammatory bowel diseases (IBD) who took the drugs during pregnancy, researchers report in the July issue of Gastroenterology. Infliximab is cleared more slowly than adalimumab from infants. However, measureable levels in infants do not seem to be

Read more
  • This is Your Brain on Anti-TNF Therapy

This is Your Brain on Anti-TNF Therapy

Anti-tumor necrosis factor (anti-TNF) agents rapidly reduce pain perception in brains of patients with Crohn’s disease, researchers show in the October issue of Gastroenterology. This observation could explain how clinical disease activity is often reduced long before signs of mucosal healing. Patients with Crohn’s disease treated with anti-TNF agents often report reductions in abdominal pain

Read more

What are the Effects of IBD Therapy During Pregnancy?

In pregnant women treated for inflammatory bowel diseases (IBD),  infliximab and adalimumab, but not certolizumab, cross the placenta and are detected in infants up to 6 months after birth, according to the March issue of Clinical Gastroenterology and Hepatology (CGH). However, they do not appear to cause birth defects, and women

Read more

Is Medicine or Surgery the Best Treatment for Crohn’s Disease?

For patients with Crohn’s disease and intra-abdominal abscesses, nonsurgical and surgical management strategies result in similar rates of abscess recurrence and complications, according to the April issue of Clinical Gastroenterology and Hepatology. Crohn’s disease can progress from inflammation and ulceration to bowel damage that includes formation of abscesses, phlegmon, and

Read more